

<b>Interview Summary</b>	<b>Application No.</b>		<b>Applicant(s)</b>	
	10/693,955		LAURIE ET AL.	
	<b>Examiner</b>		<b>Art Unit</b>	
	Humera N. Sheikh		1618	

All participants (applicant, applicant's representative, PTO personnel):

(1) Humera N. Sheikh. (3)\_\_\_\_\_

(2) Stephen J. Weyer. (4)\_\_\_\_\_

Date of Interview: 17 September 2008.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.  
If Yes, brief description: \_\_\_\_\_

Claim(s) discussed: claim 1.

Identification of prior art discussed: none.

Agreement with respect to the claims f) ☐ was reached. g) ☒ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/Humera N. Sheikh/  
Primary Examiner, Art Unit 1618

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Applicant discussed possible claim amendments to overcome the 112, 1st paragraph, new matter rejection currently of record, based on the limitation of "at least 60 mg/ml" recited in claim 1. Applicant also discussed the possibility of submitting a 37 CFR 1.132 Declaration to overcome the new matter rejection. Since application is currently under a Final Office Action, any significant amendment to the claims and/or submission of a Declaration may not be entered. Applicant's response is currently due. No further agreement was reached at this time.